Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790899 | 0.90 | MTOR (0.49) | MTORPIK3CAROCK1 | |
| SCHEMBL7911581 | 0.86 | MTOR (0.38) | MTORPIK3CAPIK3CGROCK1 | |
| SCHEMBL7913091 | 0.82 | MTOR (0.58) | MTORPIK3CAPIK3CG | |
| SCHEMBL14790923 | 0.80 | KDM4E (0.43) | MTORROCK1 | |
| SCHEMBL16310133 | 0.75 | KDM4E (0.34) | — | |
| SCHEMBL2599579 | 0.73 | MTOR (0.69) | MTORPIK3CAPIK3CG | |
| SCHEMBL7919817 | 0.73 | ALOX5AP (0.36) | PIK3CA | |
| SCHEMBL7904205 | 0.70 | PLK4 (0.41) | PIK3CA | |
| SCHEMBL14776535 | 0.70 | MTOR (0.55) | MTORPIK3CA | |
| SCHEMBL14776693 | 0.70 | MTOR (0.55) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | MTOR 1/4885PIK3CA 69/4885PDE5A 2676/4885 |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | MTOR 1/4885PIK3CA 2/4885PDE5A 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.